drugset / Trial / NCT02814461

The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC

NCT02814461

Phase 1 Completed 9 enrolled Shin Kong Wu Ho-Su Memorial Hospital
NaSingle-groupOpen-labelTreatment

Summary

To determine the maximal tolerated dose (MTD) of axitinib in combination with RT for advanced HCC.

Timeline

Start
2015-11
Primary completion
2018-11
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 1 mg
Subject Axitinib Small molecule 2 mg
Subject Axitinib Small molecule 3 mg